First in class anti-AMHRII monoclonal antibody is currently completing early clinical phases in ovarian cancer
GamaMabs Pharma sees two peer-reviewed articles published in Oncotarget, detailing the anti-tumor activity of GM102/3C23K
GamaMabs and MedImmune Enter Licensing Agreement to Develop Antibody Drug Conjugate Targeting Cancer
GamaMabs and MedImmune, the global biologics research and development arm of AstraZeneca, today announced they have entered into a licensing agreement under which GamaMabs will use MedImmune’s proprietary pyrrolobenzodiazepine (PBD) toxin and linker technology to research and produce an antibody-drug conjugate (ADC) as a potential cancer therapy.
The humanized anti-human AMHRII mAb 3C23K exerts an antitumor activity against human ovarian cancer through tumor associated macrophages
Oncotarget journal published an article on GamaMabs’GM102 antibody.
Houcine Bougherara, Fariba Némati, André Nicolas, Gérald Massonnet, Martine Pugnière, Charlotte Ngô, Marie-Aude Le Frère-Belda, Alexandra Leary, Jérôme Alexandre, Didier Meseure, Jean-Marc Barret, Isabelle Navarro-Teulon, André Pèlegrin, Sergio Roman-Roman, Jean-François Prost, Emmanuel Donnadieu1, and Didier Decaudin, (2017) The humanized anti-human AMHRII mAb 3C23K exerts an antitumor activity against human ovarian cancer through tumor associated macrophages, Oncotarget
The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells, Pauline Estupina et al., Oncotarget February 2017
Oncotarget journal published an article on GamaMabs’12G4 antibody (3C23K precursor).
Pauline Estupina, Alexandre Fontayne, Jean-Marc Barret, Nathalie Kersual, Olivier Dubreuil, Marion Le Blay, Alexandre Pichard, Marta Jarlier, Martine Pugnière, Maëva Chauvin, Thierry Chardès, Jean-Pierre Pouget, Emmanuel Deshayes, Alexis Rossignol, Toufik Abache, Christophe de Romeuf, Aurélie Terrier, Lucie Verhaeghe, Christine Gaucher, Jean-François Prost, André Pèlegrin, Isabelle Navarro-Teulon, (2017) The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells, Oncotarget
GamaMabs Pharma starts phase Ia/Ib study of first-in-class monoclonal antibody GM102 in advanced gynecological cancer
First trial of mAb targeting anti-Müllerian human receptor II tested in oncology patients
Initial results expected in 2017
GamaMabs Pharma strengthens its governance with the appointment of Martine J George, M.D., as independent board member
GamaMabs Pharma raises €15m in series B financing round
BioDiscovery 4, a fund managed by Edmond de Rothschild Investment Partners, led the round; the funds raised will finance clinical trials for GM102, a therapeutic antibody targeting gynecological cancers
GamaMabs Pharma announces the presentation of new results on 3C23K at TAT congress
GamaMabs Pharma will present new results from its collaboration with the Institut Curie at TAT meeting (Paris, March 2-4 2015) with a poster describing 3C23K antibody efficacy in combination with chemotherapy in PDX models.
Curie-Cancer and GamaMabs Pharma renew their research partnership to develop an antibody for gynecological cancers
Clinical trials are scheduled for 2015 to explore the value of the candidate drug 3C23K in relapsing ovarian cancer.
GamaMabs Pharma signs a Collaboration Agreement with Mayo Clinic
GamaMabs Pharma and Mayo Clinic will collaborate on a study on the efficacy of GamaMabs’ 3C23K antibody in ovarian patient-derived xenografts (PDX) models